| 精神分裂症患者代谢异常的病例对照研究 |
| |
| 引用本文： | 吴小立,文飞,钟智勇,陶炯. 精神分裂症患者代谢异常的病例对照研究[J]. 新医学, 2011, 42(11): 726-729 |
| |
| 作者姓名： | 吴小立 文飞 钟智勇 陶炯 |
| |
| 作者单位： | 1. 中山大学附属第三医院心理科,510630
2. 广州医学院第二附属医院心理科,510260 |
| |
| 基金项目： | 广东省科技计划项目(2009B080701080) |
| |
| 摘 要： | 目的:探讨首次接受治疗的精神分裂症患者代谢异常情况及齐拉西酮对其可能的影响.方法:病例组为29例初诊精神分裂症患者,在自然观察状态下予以齐拉西酮单药治疗4周,治疗前后分别测定其身高、体质量、腰围、臀围、总胆固醇、甘油三酯、HDL、LDL、载脂蛋白AI (aPOAI)、载脂蛋白B100 (aPOB100)、空腹血糖、空腹胰岛素及C肽,并计算胰岛素抵抗指数(IR)、腰臀比和BMI;另设健康对照组44名,于基线时同测上述指标.将病例组与健康对照组、病例组治疗前后各项代谢指标进行比较分析.结果:病例组腰臀比、空腹胰岛素、C肽及IR水平均高于健康对照组,而HDL、aPOAI水平低于健康对照组(P＜0.05或P＜0.01);病例组治疗后空腹血糖较治疗前降低.结论:精神分裂症患者本身可能已有糖脂代谢异常;非典型抗精神病药物齐拉西酮对精神分裂症患者血糖、血脂水平影响较小,有利于精神分裂症患者的长期治疗.
|
| 关 键 词： | 齐拉西酮 首次治疗 精神分裂症 病例对照 代谢异常 |
Metabolic abnormality in patients with drug-naive schizophrenia:Case-control study |
| |
| WU Xiao-li , WEN Fei , ZHONG Zhi-yong , TAO Jiong. Metabolic abnormality in patients with drug-naive schizophrenia:Case-control study[J]. New Chinese Medicine, 2011, 42(11): 726-729 |
| |
| Authors: | WU Xiao-li WEN Fei ZHONG Zhi-yong TAO Jiong |
| |
| Affiliation: | WU Xiao-li1,WEN Fei2,ZHONG Zhi-yong1,TAO Jiong1.1 Department of Psychology,The Third Affiliated Hospital of SUN Yat-sen University,Guangzhou 510630,China,2 Department of Psychology,The Second Affiliated Hospital of Guangzhou Medical college,Guangzhou,510260 |
| |
| Abstract: | Objective:To investigate the metabolic abnormality in patients with drug-naive schizophrenia and possible metabolic effect derived from ziprasidone.Methods:Oral ziprasidone treatment was carried out on 29 cases of drug-naive schizophrenia admitted patients 4 weeks under natural observational situation.The height,weight,waistline,hipline,total cholesterol,triglyceride,HDL,LDL,apolipoprotein A-1(aPOA1),apolipoprotein B100(aPOB100),fasting blood-glucose,fasting insulin and C-peptide were recorded before and af... |
| |
| Keywords: | Ziprasidone Drug-naive Schizophrenia Case-control Metabolic abnormality |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
